Recombinant Rabbit Ctsk protein, His-tagged

• Cat.No.: Ctsk-2763R
• Product Overview: Recombinant Rabbit Ctsk protein(P43236)(115-329aa), fused to N-terminal His tag, was expressed in E. coli.

Specification

• Source: E. coli
• Species: Rabbit
• Tag: His
• Form: If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
  If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
• Molecular Mass: 27.6 kDa
• Protein length: 115-329aa
• AA Sequence: TPDSIDYRKKGYVTPVKNQGQCGSC WAFSSVGALEGQLKKKTGKLLNLSP QNLVDCVSENYGCGGGYMTNAFQYV QRNRGIDSEDAYPYVGQDESCMYNP TGKAAKCRGYREIPEGNEKALKRAV ARVGPVSVAIDASLTSFQFYSKGVY YDENCSSDNVNHAVLAVGYGIQKGN KHWIIKNSWGESWGNKGYILMARNK NNACGIANLASFPKM
• Purity: Greater than 90% as determined by SDS-PAGE.
• Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
• Reconstitution: Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%.

Gene Information

• Gene Name: CTSK cathepsin K [ Oryctolagus cuniculus ]
• Official Symbol: Ctsk
• Synonyms: CTSK; cathepsin K; protein OC-2; OC-2
• Gene ID: 100009334
• mRNA Refseq: NM_001082641
• Protein Refseq: NP_001076110

Reviews

09/13/2019

This guidance can help researchers design and execute their experiments more effectively, ensuring reliable and accurate results.

01/27/2019

They have a deep understanding of the CTSK protein and can provide valuable insights into its characteristics, properties, and optimal experimental conditions.

12/14/2016

the manufacturer offers outstanding technical support, serving as a valuable resource to resolve any issues that may arise during my research.

Q&As

Can CTSK be a target for the development of novel therapeutics for periodontal diseases?

Yes, CTSK inhibitors are being investigated for their potential in preventing bone loss associated with periodontal diseases.

How does CTSK contribute to the progression of atherosclerosis, and can it be a therapeutic target for cardiovascular diseases?

CTSK has been linked to vascular calcification in atherosclerosis, and inhibiting its activity may have potential as a therapeutic strategy for cardiovascular diseases.

How might CTSK inhibitors impact the treatment landscape for bone metastasis in cancer patients?

CTSK inhibitors could potentially be used to limit bone destruction in cancer patients with bone metastasis, improving their quality of life.

Are there any other medical conditions where CTSK inhibitors could be beneficial?

CTSK inhibitors are being explored for potential therapeutic applications in conditions like rheumatoid arthritis and certain cancers due to their involvement in tissue remodeling.

Are there diagnostic applications for CTSK in identifying bone-related disorders?

While CTSK is not currently used as a diagnostic marker, its levels and activity could potentially be explored for diagnostic purposes in the future.